Pharma Focus Europe

Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline

Tuesday, November 29, 2022

Full-Life Technologies, a global radiotherapeutics company, has announced its agreement to acquire Focus-X Therapeutics, a New Jersey-based company specializing in targeted radiopharmaceuticals for cancer treatment. Focus-X utilizes proprietary peptide engineering technology in its development of these therapeutics. The acquisition will expand Full-Life's pipeline by adding two compounds close to clinical trials and introducing a second innovative peptide discovery platform. Full-Life will leverage its Radio Technology manufacturing and logistics platforms to advance these compounds into clinical development.

As per the terms of the acquisition, Focus-X shareholders will be eligible to receive an upfront payment from Full-Life, along with potential milestones based on development, regulatory approvals, and sales, totaling up to $245 million. Additionally, Focus-X will receive royalties on any commercial sales resulting from the acquisition. The completion of the acquisition is expected in the first quarter of 2023.

Lanny Sun, Co-founder, Chairman, and CEO of Full-Life, stated, "The Focus-X acquisition perfectly complements Full-Life's radiotechnology and development platform by incorporating two development-ready compounds, including a lead compound with initial human data, a robust pipeline, and world-class peptide discovery capabilities."

Dr. Fa Liu, Co-founder and CEO of Focus-X, added, "Full-Life's integrated platforms will provide us with manufacturing technology, logistics support, and clinical development expertise to accelerate the development of our compounds and expand our discovery efforts. This world-class radiopharmaceutical team has enormous potential to develop therapeutics that impact patients worldwide."

Focus-X, founded in 2020, has established a proprietary engineering platform for the development of peptide radioligands, which precisely deliver alpha or beta emitters to target cancer cell DNA. This platform allows for the optimization of peptide radioligand vectors, focusing on key pharmaceutical attributes such as biodistribution, binding affinity, and in vivo stability. The company's approach overcomes challenges faced by other ligand targeting compounds, such as antibodies. Focus-X has concentrated on both validated targets and new mechanisms.

The company has built a substantial pipeline, with its two lead compounds in development being a prostate-specific membrane antigen (PSMA)-targeted peptide for metastatic castration-resistant prostate cancer and a neurotensin receptor type 1 (NTSR1)-targeted peptide for pancreatic cancer treatment. The PSMA-targeted compound is currently undergoing an investigator-initiated imaging study. In addition to these lead compounds, Focus-X has six other programs in earlier stages of development.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva